• Explore /
  • Poster
  • / First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B.

First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B.

Abstract Poster

Authors

Jae-Lyun Lee

Jae-Lyun Lee

Asan Medical Center and University of Ulsan College of Medicine, Seoul, South Korea

Jae-Lyun Lee , Marek Ziobro , Cristina Suarez , Przemyslaw Langiewitz , Vsevolod Borisovich Matveev , Pawel Wiechno , Rustem Gafanov , Piotr Tomczak , Frédéric Pouliot , Frede Donskov , Boris Alekseev , Sang Joon Shin , Georg A. Bjarnason , Daniel Castellano , Xiaoqi Du , Rodolfo F. Perini , Karla Rodriguez-Lopez , David F. McDermott , Michael B. Atkins

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT02853344

Citation

J Clin Oncol 38: 2020 (suppl; abstr 5034)

DOI

10.1200/JCO.2020.38.15_suppl.5034

Abstract #

5034

Poster Bd #

103

Abstract Disclosures

Similar Posters

First Author: David F. McDermott

First Author: Jae-Lyun Lee

First Author: Ivan Borbath

First Author: Scott S. Tykodi